References
- Brownlee K. A. Simple linear regression. Introduction to Statistical Analysis, W. J. Dixon, F. J. Massey. McGraw-Hill, New York 1969; 334–396
- Cersosimo R. J., Bromer R., Licciardello J. T. W., Hong W. K. Pharmacology, clinical efficacy and adverse effects of vindesine sulfate, a new vinca alkaloid. Pharmacotherapy 1983; 3: 259–274
- Chong C. D. K., Logothetis C. J., Savaraj N., Fritsche H. A., Gietner A. M., Samuels M. L. The correlation of vinblastine pharmacokinetics to toxicity in testicular cancer patients. Journal of Clinical Pharmacology 1988; 28: 714–718
- Delbarre B., Granger C., Grosse R., Wright M., Paraire M., Bizzari J. P. S12363 a new vinca alkaloid derivative inducing a particular spiralization of microtubules. Proceedings of the American Association for Cancer Research Journal 1990; 31: 401
- Draper N. R., Smith H. Fitting a straight line by least squares. Applied Regression Analysis, N. R. Draper, H. Smith. John Wiley, New York 1966; 7–26
- Egorin M. J., Van Echo D. A., Whitacre M. Y., Forrest A., Sigman L. M., Engisch K. L., Aisner J. Human pharmacokinetics, excretion, and metabolism of the anthracycline antibiotic menogaril ‘7-OMEN, NSC 269148’ and their correlation with clinical toxicities. Cancer Research 1986; 46: 1513–1520
- Egorin M. J., Conley B. A., Forrest A., Zuhowski E. G., Sinibaldi V., Van Echo D. A. Phase I study and pharmacokinetics of menogaril (NSC 269148) in patients with hepatic dysfunction. Cancer Research 1987a; 47: 6104–6110
- Egorin M. J., Sigman L. M., Van Echo D. A., Forrest A., Whitacre M. Y., Aisner J. Phase I clinical and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580) administered as a five-day continuous infusion. Cancer Research 1987b; 47: 617–623
- Gibaldi M., Perrier D. Drugs and the Pharmaceutical Sciences. Pharmacokinetics. Second edition, M. Gibaldi, D. Perrier. Marcel Dekker, New York 1982, Revised and Expanded
- Ings R. M. J., Pidgen A., Johnson D. Analysis of bioavailability studies. World Conference on Clinical Pharmacology and Therapeutics, P. Turner, C. Padgham. Macmillan Press, London 1980, Abstract No. 0416
- Metzler C. M., Weiner D. L. PC NONLIN User Guide—Version 3.0. SCI Software Statistical Consultants Inc., KentuckyUSA 1989
- Nelson R. L., Dyke R. W., Root M. A. Comparative pharmacokinetics of vindesine, vincristine and vinblastine in patients with cancer. Cancer Treatment Reviews 1980; 7(Suppl.)17–24
- Pierré A., Kraus-Berthier L., Atassi G., Cros S., Poupon M.-F., Lavielle G., Berlion M., Bizzari J.-P. Preclinical antitumour activity of a new Vinca alcaloid derivative, S12363. Cancer Research 1991; S1: 2312–2318
- Rahmani R., Bruno R., Iliadis A., Favre R., Just S., Barbet J., Cano J.-P. Clinical pharmacokinetics of the antitumour drug navelbine (5′-noranhydrovinblastine). Cancer Research 1987; 47: 5796–5799
- Rahmani R., Samak R., Bore P., Cano J.-P. Pharmacocinetique clinique des vinca-alcaloides. Bulletin of Cancer 1988; 75: 195–200
- Ratain M. J., Volelzang N. J., Sinkule J. A. Interpatient and intrapatient variability in vinblastine pharmacokinetics. Clinical Pharmacology and Therapeutics 1987; 41: 1–66
- Sandler S. G., Tobin W., Henderson E. S. Vincristine-induced neuropathy. A clinical study of 50 leukemic patients. Neurology 1969; 19: 367–374
- Vendrig D. E. M. M., Teeuwsen J., Holthuis J. J. M., de Vries E. G. E., Mulder N. H., Smit E. F., Postmus P. E. Pharmacokinetics of vincristine. Proceedings of the American Association of Cancer Research 1988; 29: 221